Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 8
Submit an article Journal homepage
4,517
Views
31
CrossRef citations to date
0
Altmetric
Diabetes

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Priscilla HollanderBaylor Endocrine Center, Dallas, TX, USA;
,
Julie HillMerck & Co. Inc., Kenilworth, NJ, USA;
,
Jeremy JohnsonMerck & Co. Inc., Kenilworth, NJ, USA;
,
Zhi Wei JiangMSD R&D (China) Co. Ltd, Beijing, China;
,
Gregory GolmMerck & Co. Inc., Kenilworth, NJ, USA;
,
Susan HuyckMerck & Co. Inc., Kenilworth, NJ, USA;
,
Steven G. TerraPfizer Inc., Andover, MA, USA;
,
James P. MancusoPfizer Inc., Groton, CT, USA;
,
Samuel S. EngelMerck & Co. Inc., Kenilworth, NJ, USA;
,
Brett Lauringformerly of Merck & Co. Inc., Kenilworth, NJ, USA; ;Currently at Takeda Pharmaceuticals, Cambridge, MA, USA
&
Jie LiuMerck & Co. Inc., Kenilworth, NJ, USA; Correspondence[email protected]
 show all
Pages 1335-1343 | Received 22 Oct 2018, Accepted 08 Feb 2019, Published online: 25 Mar 2019

Related Research Data

8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
Source: American Diabetes Association
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Source: Springer Science and Business Media LLC
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Source: Elsevier BV
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Source: Wiley
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Source: American Diabetes Association
A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents
Source: American Diabetes Association
Ertugliflozin in type 2 diabetes: a profile of its use
Source: Springer Science and Business Media LLC
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Source: Wiley
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Source: Springer Science and Business Media LLC
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
Source: Wiley
Comparative analysis of two rates
Source: Wiley

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.